FeesSafety
Pluang+

Foghorn Therapeutics faces securities fraud probe after halting key drug programs and cutting 40% workforce.

Market News
13 Oct 2026, 23:37 WIB
GlobeNewsWire
View Source
Bearish
Foghorn Therapeutics faces securities fraud probe after halting key drug programs and cutting 40% workforce.

Foghorn Therapeutics announced it will not advance its FHD-909 and SMARCA2 degrader programs, ending collaboration with Lilly and cutting its workforce by 40%. Following this, its stock dropped over 30%. Pomerantz LLP is investigating whether Foghorn and its executives engaged in securities fraud or other unlawful practices. The investigation could impact investors as the company refocuses on other proprietary programs with long-term goals.

Foghorn Therapeutics faces a 40% workforce cut and halted drug programs amid a securities investigation. For readers following the health sector, here is Pluang's market snapshot as of Oct 14, 2026 03:02 WIB: out of 128 priced US health stocks, 28 rose and 100 fell. Notable movers include VRTX at USD 485.08 (-4.32%), RXRX at USD 3.84 (-4.24%), and NBIX at USD 135.50 (-4.15%), with varied Pluang order activity and typical hold times.

More News

Ipsos discloses share buyback trades from Nov 9-13, 2026, showing steady repurchases at around €36 per share.

Ipsos discloses share buyback trades from Nov 9-13, 2026, showing steady repurchases at around €36 per share.

Ipsos reported its share buyback activity from November 9 to 13, 2026, purchasing thousands of its own shares daily on multiple trading platforms at prices near €36 each. This ongoing buyback program reflects the company's strategy to return value to...

Company Fundamentals
Neutral
1 hour ago
Ipsos repurchased over 80,000 shares from Nov 9-13, 2026, at average prices around €36 each.

Ipsos repurchased over 80,000 shares from Nov 9-13, 2026, at average prices around €36 each.

Between November 9 and 13, 2026, Ipsos conducted a share buyback program, repurchasing a total of more than 80,000 ordinary shares across different markets. The average purchase price per share ranged around €36. This move reflects Ipsos's strategy t...

Company Fundamentals
Neutral
1 hour ago
Lightspark launches Agent Accounts enabling AI agents to make payments globally with Visa and multiple currencies.

Lightspark launches Agent Accounts enabling AI agents to make payments globally with Visa and multiple currencies.

Lightspark has introduced Agent Accounts, a new payment solution allowing AI agents to hold, spend, send, and receive money on behalf of individuals or businesses across various currencies and payment methods. This service supports payments at over 1...

Others
Bullish
1 hour ago
Bernstein SocGen raises Humana price target to $515 amid strong stock gains and new Gold Card program launch.

Bernstein SocGen raises Humana price target to $515 amid strong stock gains and new Gold Card program launch.

Bernstein SocGen Group has raised its price target for Humana to $515, reflecting confidence in the health insurer's strong performance. Humana shares have surged 80.1% year-to-date and recently hit a 52-week high of $462.87. The company plans to lau...

Analyst Insights
Bullish
2 hours ago
Amer Sports beats Q3 earnings estimates and raises full-year guidance on strong growth.

Amer Sports beats Q3 earnings estimates and raises full-year guidance on strong growth.

Amer Sports reported Q3 2026 earnings per share of $0.42, surpassing the analyst estimate of $0.36, with revenue of $2.17 billion beating the $2.14 billion forecast. The company saw 24% revenue growth and margin expansion, driven by strong performanc...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App